ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
ABC27,
Study successfully achieved both primary and secondary objectives ANAVEX®2-73 treatment resulted in improvements of all…